Clinical trials
Observational Colitis, Ulcerative trials in Germany
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
41 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 2 |
| 2004 | 2 |
| 2006 | 1 |
| 2007 | 1 |
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 3 |
| 2012 | 2 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 4 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 2 |
| 2019 | 3 |
| 2021 | 3 |
| 2022 | 4 |
| 2023 | 1 |
| 2024 | 5 |
| 2025 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 15 |
| Active, not recruiting | 7 |
| Recruiting | 7 |
| Terminated | 6 |
| Unknown status | 5 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| University of Erlangen-Nürnberg Medical School | 7 |
| AbbVie | 4 |
| Ferring Pharmaceuticals | 3 |
| Ced Service GmbH | 2 |
| Pfizer | 2 |
| Universität Duisburg-Essen | 2 |
| Alfasigma S.p.A. | 1 |
| Biogen | 1 |
| Bristol-Myers Squibb | 1 |
| Charite University, Berlin, Germany | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Colitis, Ulcerative | 41 |
| Crohn Disease | 21 |
| Inflammatory Bowel Diseases | 13 |
| Colitis | 3 |
| Gastroenteritis | 2 |
| Gastrointestinal Diseases | 2 |
| Intestinal Diseases | 2 |
| Irritable Bowel Syndrome | 2 |
| Rheumatic Diseases | 2 |
| Arthritis, Psoriatic | 1 |
Trials
Showing 1 to 25 of 41. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.